Nafamostat Mesilate as an Anticoagulant During Continuous Renal Replacement Therapy in Patients With High Bleeding Risk: A Randomized Clinical Trial

Nafamostat mesilate (NM), a synthetic serine protease inhibitor, has been used increasingly as an anticoagulant during continuous renal replacement therapy (CRRT). However, there, are limited data from randomized studies on NM use in patients with a bleeding tendency. This prospective study evaluate...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Medicine (Baltimore)
Hlavní autoři: Choi, Ji-Young, Kang, Yun-Jeong, Jang, Hye Min, Jung, Hee-Yeon, Cho, Jang-Hee, Park, Sun-Hee, Kim, Yong-Lim, Kim, Chan-Duck
Médium: Artigo
Jazyk:Inglês
Vydáno: Wolters Kluwer Health 2015
Témata:
5200
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5291631/
https://ncbi.nlm.nih.gov/pubmed/26717390
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000002392
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky